Related Experiment Video
Updated: Feb 28, 2026
06:32
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
8.3K
Actionable molecular biomarkers in primary brain tumors
Verena Staedtke1,2, Omar Dildar a Dzaye1,3,4, Matthias Holdhoff1,5
1Brain Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
Trends in Cancer
|June 13, 2017
Summary
Molecular biomarkers are revolutionizing brain cancer research, offering new avenues for treatment. Key markers like MGMT promoter methylation and IDH1/2 mutations are crucial for guiding clinical decisions in neuro-oncology.
Area of Science:
- Neuro-oncology
- Genomics
- Molecular Biology
Background:
- Genome-wide studies have significantly advanced the understanding of central nervous system (CNS) tumor biology.
- This progress opens opportunities for biomarker-driven clinical research in neuro-oncology.
- However, limited molecular markers currently impact clinical decision-making and treatment strategies.
Purpose of the Study:
- To review currently impactful biomarkers in adult and pediatric brain cancers.
- To provide a perspective on future research directions in neuro-oncology biomarkers.
Main Methods:
- Review of current literature on validated molecular markers in neuro-oncology.
- Focus on biomarkers influencing clinical practice and research.
Main Results:
- MGMT promoter methylation is a key prognostic and predictive marker for glioblastoma.
- Co-deletion of 1p and 19q is crucial for differentiating oligodendrogliomas from astrocytomas.
- IDH1/2 mutations and other pathway-associated mutations are also significant markers.
Conclusions:
- Validated molecular markers are essential for advancing neuro-oncology.
- Continued research into biomarkers will drive personalized treatment strategies for brain cancers.
- The identified biomarkers are critical for current clinical decision-making and future therapeutic development.
